ArticleNEJM AI2026
LLM-Assisted Reanalysis of Unsolved Rare Disease Genomes Increases Diagnostic Yield.
Article in NEJM AI, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundRare and undiagnosed genetic disorders affect millions of patients globally, and many patients endure years of inconclusive testing. Conventional genomic interpretation can be insufficiently sensitive and costly and is rarely repeated as knowledge evolves.
methodsWe conducted a retrospective multicohort reanalysis using a large language model (LLM)-assisted workflow that ingests clinician notes, Human Phenotype Ontology (HPO) terms, and a filtered variant table to propose explanation-rich candidate hypotheses for expert adjudication under American College of Medical Genetics and Genomics and Association for Molecular Pathology criteria. A diagnosis was defined a priori as a variant classified as pathogenic or likely pathogenic, confirmed in a Clinical Laboratory Improvement Amendments-certified laboratory, and returned to families. Secondary outputs included "rediscoveries" of externally established diagnoses not yet available locally and hypothesis generation signals.
resultsAcross four cohorts, new local diagnoses were made in 10 of 100 rare disease neurodevelopmental cases (10.0%, [exact binomial: 95% confidence interval (CI), 4.9 to 17.6]), 4 of 61 neuromuscular cases (6.6%, [CI, 1.8 to 16.0]), 2 of 200 cases of sudden unexpected death in pediatrics (1.0% [CI, 0.1 to 3.6]), and 2 of 15 early psychosis cases (13.3% [CI, 1.7 to 40.5]) for an overall diagnostic yield of 18 of 376 (4.8%, [CI, 2.9 to 7.5]). We identified seven rediscoveries in which pathogenic or likely pathogenic findings had been established externally but were not available in the local research record at the time of review. In one case, the model's synthesis of genotype-quality patterns and phenotype concordance triaged a putative 22q11.2 deletion that was subsequently confirmed by whole-genome sequencing. The workflow also generated testable biological hypotheses, including a candidate association between the sphingosine-1-phosphate receptor 1 gene (
conclusionsIn retrospective reanalysis, an explanation-first LLM applied to routine HPO terms and variant tables produced clinically relevant gains in diagnostic yield, surfaced overlooked pathogenic findings, and generated biologically grounded hypotheses. These results motivate prospective multicenter evaluation with predefined end points, calibration reporting, and comparator baselines. (Funded by the U.S. National Institute of Child Health and Human Development and others.).
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.